Want to see OMCL full AI Analyst Report?
Top Page
Omnicell
(NASDAQ:OMCL)
Select Model
Select Model
Rating:63Neutral
Price Target:
$40.00
▼(-2.44% Downside)
Action:Reiterated
Date:08/18/26
OMCL scores 63 primarily due to improved financial stability (low leverage and solid, consistent free cash flow) and a generally constructive earnings update with raised full-year profitability targets. The score is held back by weak technical momentum (price below major moving averages with negative MACD) and an expensive valuation (P/E 43.63) alongside near-term execution risks flagged on the call (booking timing uncertainty, non-recurring Q2 benefit, and margin headwinds).
Positive Factors
Revenue and Profitability Rebound
The sharp revenue recovery and improved operating margin indicate better execution and renewed demand for Omnicell’s solutions. If sustained, this can strengthen earnings power, support reinvestment and improve profitability despite the company’s historically uneven results.
Negative Factors
Thin and Historically Volatile Profitability
Despite the recent rebound, limited bottom-line margin leaves earnings sensitive to cost increases, revenue timing and execution setbacks. The history of losses also suggests that improved profitability is not yet fully established as a durable operating characteristic.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profitability Rebound
The sharp revenue recovery and improved operating margin indicate better execution and renewed demand for Omnicell’s solutions. If sustained, this can strengthen earnings power, support reinvestment and improve profitability despite the company’s historically uneven results.
Read all positive factors
Omnicell Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how revenue is distributed among various business segments, indicating which areas drive growth and where strategic focus might be needed.
Shows how revenue is distributed among various business segments, indicating which areas drive growth and where strategic focus might be needed.
Data provided by:
The Fly
The FlyOmnicell (OMCL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.62B
Dividend YieldN/A
Average Volume (3M)719.86K
Price to Earnings (P/E)41.6
Beta (1Y)0.79
Revenue Growth8.45%
EPS Growth72.08%
CountryUS
Employees3,485
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.85
Shares Outstanding45,614,883
10 Day Avg. Volume689,632
30 Day Avg. Volume719,864
Financial Highlights & Ratios
PEG Ratio-12.17
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$55.00Price Target Upside34.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)2.26
Revenue Forecast (FY)$1.24B
Omnicell Business Overview & Revenue Model
Company Description
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the h...
How the Company Makes Money
Omnicell makes money primarily by selling medication management and pharmacy automation products, licensing software, and providing ongoing services that support implementation and continued operation.
Key revenue streams typically include:
- Pro...
Omnicell Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call presents solid operating and financial execution in Q2 — revenue at the high end of guidance, strong cash generation, several strategic product wins and a materially larger pipeline — coupled with raised full-year profitability targets. However, key near-term risks include timing uncertainty around large product bookings (broad bookings range), a one-time tariff refund that boosted Q2 results, memory chip cost pressures (~$6M impact, ~50–80 bps margin effect), and slower consumables/ARR timing. Overall, the tone balances strong execution and long-term opportunity against near-term timing and supply-chain headwinds.Positive Updates
Revenue at Top of Guidance
Total revenue of $312.0M in Q2 2026, reported at the high end of prior guidance, driven by product revenue of $175M and service revenue of $137M.
Negative Updates
Wide Product Bookings Range and Timing Uncertainty
Full-year product bookings guidance was revised to a wide range of $425M–$560M with the bottom end materially lowered to reflect timing uncertainty on medium and large deals; management emphasized multi-quarter to multi-year capital approval cycles and potential push of some bookings into 2027.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue at Top of Guidance
Total revenue of $312.0M in Q2 2026, reported at the high end of prior guidance, driven by product revenue of $175M and service revenue of $137M.
Read all positive updates
Company Guidance
Omnicell’s guidance for Q3 2026 is total revenue $301–307M, product revenue $169–172M, service revenue $132–135M, non‑GAAP EBITDA $32–37M and non‑GAAP EPS $0.35–0.43 (assuming ~18% non‑GAAP tax rate); the company reminded listeners Q2 results were $312M total revenue (product $175M, services $137M) with non‑GAAP EBITDA $67M (would have been $52M excl. a $15M tariff refund), non‑GAAP EPS $0.94, GAAP EPS $0.52, cash $292M and free cash flow $56M. For full‑year 2026 Omnicell updated guidance to product bookings $425–560M, total revenue $1.225–1.245B, product revenue $690–700M, service revenue $535–545M, year‑end ARR $660–680M, non‑GAAP EBITDA $175–185M and non‑GAAP EPS $2.15–2.30, while flagging a ~$6M incremental H2 memory‑cost headwind (~50 bps consolidated gross‑margin and ~80 bps product gross‑margin impact) and saying the wider bookings range reflects timing uncertainty rather than weaker demand.Omnicell Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
76
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.25B | 1.18B | 1.11B | 1.15B | 1.30B | 1.13B |
| Gross Profit | 558.13M | 508.04M | 471.00M | 499.93M | 588.99M | 554.65M |
| EBITDA | 106.06M | 101.87M | 119.87M | 79.98M | 96.85M | 173.33M |
| Net Income | 39.08M | 2.05M | 12.53M | -20.37M | 5.65M | 77.85M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 1.97B | 2.12B | 2.23B | 2.21B | 2.14B |
| Cash, Cash Equivalents and Short-Term Investments | 307.01M | 211.17M | 381.68M | 479.84M | 341.85M | 359.72M |
| Total Debt | 200.00M | 204.34M | 382.55M | 614.09M | 616.74M | 541.01M |
| Total Liabilities | 707.25M | 742.91M | 877.65M | 1.04B | 1.08B | 995.81M |
| Stockholders Equity | 1.29B | 1.23B | 1.24B | 1.19B | 1.13B | 1.15B |
Cash Flow | ||||||
| Free Cash Flow | 141.40M | 86.89M | 151.26M | 139.62M | 17.04M | 202.84M |
| Operating Cash Flow | 182.67M | 127.30M | 187.72M | 181.09M | 77.78M | 231.81M |
| Investing Cash Flow | -57.10M | -60.36M | -52.79M | -55.02M | -58.67M | -412.50M |
| Financing Cash Flow | -240.02M | -218.32M | -235.58M | 23.42M | -20.95M | 47.36M |
Omnicell Technical Analysis
Negative
41.00
Price Trends
40.24
Negative
40.33
Negative
40.79
Negative
Market Momentum
-1.49
Positive
37.30
Neutral
17.66
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Negative. The current price of 41 is above the 20-day moving average (MA) of 37.46, above the 50-day MA of 40.24, and above the 200-day MA of 40.79, indicating a bearish trend. The MACD of -1.49 indicates Positive momentum. The RSI at 37.30 is Neutral, neither overbought nor oversold. The STOCH value of 17.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OMCL.
Omnicell Risk Analysis
Omnicell disclosed 33 risk factors in its most recent earnings report. Omnicell reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Omnicell Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $8.48B | -110.37 | -9.33% | ― | -4.28% | 15.82% | |
66 Neutral | $1.18B | 65.59 | 2.61% | ― | -1.83% | -48.77% | |
65 Neutral | $1.29B | -19.01 | -6.66% | ― | 0.66% | -134.07% | |
63 Neutral | $1.62B | 41.62 | 3.13% | ― | 8.45% | 72.08% | |
59 Neutral | $535.90M | -1.06 | -99.16% | ― | -4.50% | -184.71% | |
52 Neutral | $1.16B | -6.45 | -13.08% | ― | -2.08% | 16.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
OMCL
Omnicell
35.58
2.49
7.52%
EVH
Evolent Health
4.74
-4.96
-51.13%
TDOC
Teladoc
6.39
-1.28
-16.69%
TXG
10x Genomics
65.12
51.05
362.83%
GDRX
GoodRx Holdings
3.45
-0.80
-18.82%
CERT
Certara
8.43
-2.38
-22.02%
Omnicell Corporate Events
Business Operations and StrategyExecutive/Board Changes
Omnicell Elevates COO Nnamdi Njoku to President
Positive
Jul 1, 2026
On June 30, 2026, Omnicell’s board appointed Chief Operating Officer Nnamdi Njoku as President, effective July 1, 2026, with CEO and Chairman Randall Lipps stepping down from the president role but retaining his other positions and strategic...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Omnicell Stockholders Approve Governance Changes and Incentive Plan
Positive
May 26, 2026
On May 19, 2026, Omnicell stockholders held their Annual Meeting and approved all five proposals, including the election of three Class I directors, an advisory endorsement of named executive officer compensation, an expansion of the 2009 Equity I...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.